Latest stock research reports with share price targets forecast, buy, hold, and sell recommendations along with upside. Search by company or broker name.
Distribution and Export Growth: Coromandel's extensive domestic and international distribution network to expand NACL's market reach, support domestic sales and accelerate export recovery. Product-Mix Improvement: Increased focus on formulations, intermediates and CDMO opportunities along with stronger technical capabilities to improve product mix and profitability. Lean Balance Sheet: Post-rights issue, NACL's stronger balance sheet and lower leverage provide greater financial flexibility to support...
A life sciences workflow outsourcing growth story - Indegene, founded in 1998, is a digital-first commercialization partner focused on the global life sciences industry. It serves 20/20 top biopharma companies and operates across 80+ markets through 17+...
: Pearl Global Industries Ltd. (PGIL) is a multi-national apparel manufacturer offering end-to end sustainable solutions across the fashion value chain. It has 25 manufacturing facilities with capacity of ~108mn pieces across...
Asian markets were trading lower this morning, except the Nikkei, which gained 1.13%. The Hang Seng and Shanghai declined 1.46% and 1.22%, respectively.
Global outsourcing of pharma R&D/testing, tightening food-safety and export - compliance norms, and India's cost/talent advantage drive multi - year demand for accredited CRTO capacity. Unlike acquisition - led peers, Vimta has grown organically adding ~200,000 sq .ft. at its Genome Valley Life Sciences campus (~INR 100 Cr, FY 25- 26) and doubling EMI/EMC chamber capacity for defence - electronics demand.
The consultation paper released yesterday recommends significant changes to commissions. PB Fintech hosted a call to discuss the implications and indicated that, if implemented as proposed, the changes could result in a potential 30% hit to FY28 core online insurance revenue.
Niva Bupa hosted a conference call to discuss the implications of the consultation paper released on distribution regulations. The company believes that the measures in the draft would be a net positive for the industry and the company.
Global life science and pharma companies prefer to onboard external agencies like Indegene to reduce operational costs, accelerate go-tomarket, access specialized global talent, and manage the spike in content volume during the drug launch and drop during periods with no updates.
Pearl Global’s (PGIL) analyst meet reinforces a structurally stronger mid-to-high teens growth framework (16–18%), with management targeting ~15% volume growth and ~300bp margin expansion (12-14% EBITDA margin), driven by operating leverage and a higher contribution from knit products.
PGIL guides for ~18% revenue CAGR (backed by ~15% volume CAGR) to achieve ~$1bn revenue by FY30. This would be achieved by expanding the capacity base to ~170mn pcs by FY30 vs ~101mn pcs in FY26 (keeping geographical mix constant).
DLPL has announced the acquisition of SN Genelab—a B2B diagnostics operator focused on advanced genomics and molecular pathology testing—for Rs1.68bn (70% stake), thus valuing the company at ~16x FY26 EV/EBITDA.
We attended MMFS’s CPC, branch, and tractor dealer visits, where the management showcased Project Udaan, the MTezz app, and the Samur.AI stack. Tech-driven processes have reduced in-principle approvals to under 20min and end-to-end TAT from 8–10 days to 1–2 days.
